TABRECTA
Total Payments
$11.6M
Transactions
3,686
Doctors
1,785
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 31 | 9 |
| 2023 | $5.4M | 1,607 | 976 |
| 2022 | $3.0M | 892 | 488 |
| 2021 | $1.6M | 908 | 545 |
| 2020 | $162,535 | 248 | 161 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.3M | 205 | 96.9% |
| Consulting Fee | $270,354 | 101 | 2.3% |
| Food and Beverage | $64,655 | 3,353 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,750 | 4 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $5,900 | 2 | 0.1% |
| Travel and Lodging | $3,853 | 20 | 0.0% |
| Education | $12.00 | 1 | 0.0% |
Payments by Type
Research
$11.3M
205 transactions
General
$354,524
3,481 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Neratinib and Capmatinib combination in metastatic breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia Signaling Analysis Test | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N) | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| A Phase I/II Study of Capmatinib Plus Trametinib in Patients with Metastatic MET exon 14 Skipping Mutation Positive NSCLC | Novartis Pharmaceuticals Corporation | $1.4M | 0 |
| A PHASE II MULTICENTER THREE COHORT STUDY OF ORAL CMET INHIBITOR INC280 IN ADULT PATIENTS WITH EGFR WILD TYPE WT ADVANCED NON SMALL CELL LUNG CANCER NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FORADVANCED METASTATIC DISEASE | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| PHASE II TRIAL OF NEOADJUVANT AND ADJUVANT CAPMATINIB IN PARTICIPANTS WITH STAGES IB-IIIA, N2 AND SELECTED IIIB (T3N2 OR T4N2) NSCLC WITH MET EXON 14 SKIPPING MUTATION OR HIGH MET AMPLIFICATION (GEOMETRY-N) | Novartis Pharmaceuticals Corporation | $1.2M | 3 |
| An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A phase II multicenter three cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild type wt advanced non small cell lung cancer NSCLC who have received one or two prior lines of systemic therapy foradvanced metastatic disease | Novartis Pharmaceuticals Corporation | $521,768 | 0 |
| A PHASE III RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF CAPMATINIB IN COMBINATION WITH OSIMERTINIB VERSUS PLATINUM - PEMETREXED BASED DOUBLET CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR ACTIVATING | Novartis Pharmaceuticals Corporation | $508,515 | 0 |
| A PHASE I AND OR II STUDY OF THE CMET INHIBITOR INC280 IN COMBINATION WITH BEVACIZUMAB ADMINISTERED AS 2ND LINE THERAPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME | Novartis Pharmaceuticals Corporation | $423,540 | 0 |
| A PHASE I/II STUDY OF CAPMATINIB PLUS TRAMETINIB IN PATIENTS WITH METASTATIC MET EXON 14 SKIPPING MUTATION POSITIVE NSCLC | Novartis Pharmaceuticals Corporation | $385,647 | 0 |
| NERATINIB AND CAPMATINIB COMBINATION IN METASTATIC BREAST CANCER PATIENTS WITH ABNORMAL HER2 AND C-MET PATHWAY ACTIVITY AS MEASURED BY THE CELSIGNIA SIGNALING ANALYSIS TEST | Novartis Pharmaceuticals Corporation | $344,929 | 0 |
| A phase 2 open-label study to determine the central nervous system efficacy of Capmatinib in NSCLC patients with brain metastases with cfDNA positive MET alterations | Novartis Pharmaceuticals Corporation | $252,954 | 0 |
| A PHASE III RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF CAPMATINIB IN COMBINATION WITH OSIMERTINIB VERSUS PLATINUM - PEMETREXED BASED DOUBLET CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR ACTIVATING MUTATIONS WHO HAVE PROGRESSED ON PRIOR GENERATION EGFR-TKI THERAPY AND WHOSE TUMORS ARE T790M MUTATION NEGATIVE AND HARBOR MET AMPLIFICATION (GEOMETRY-E) | Novartis Pharmaceuticals Corporation | $215,100 | 0 |
| A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E) | Novartis Pharmaceuticals Corporation | $133,933 | 0 |
| A PHASE 2 STUDY OF THE MET KINASE INHIBITOR INC280 IN PAPILLARY RENAL CELL CANCER | Novartis Pharmaceuticals Corporation | $96,161 | 0 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $49,997 | 9 |
| A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1? 50% | Novartis Pharmaceuticals Corporation | $44,396 | 0 |
| A DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB AND SPARTALIZUMAB VS CAPMATINIB AND PLACEBO AS 1ST LINE TREATMENT FOR ADVANCED NSCLC PATIENTS WITH MET EXON14 SKIPPING MUTATIONS | Novartis Pharmaceuticals Corporation | $35,548 | 0 |
| A PHASE II MULTICENTER RANDOMIZED TWO ARM STUDY OF THE COMBINATION OF CAPMATINIB INC280 AN ORAL MET INHIBITOR AND SPARTALIZUMAB PDR001 A PD 1 INHIBITOR VERSUS DOCETAXEL IN PRETREATED ADULT PATIENTS WITH EGFR WILD TYPE ALK REARRANGEMENT NEGATIVE LOCALLY ADVANCED METASTATIC NON SMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $4,000 | 0 |
| CINC280J12201 | Novartis Pharma AG | $3,859 | 0 |
Top Doctors Receiving Payments for TABRECTA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlotte, NC | $11.2M | 194 |
| , MD | Hematology & Oncology | Orlando, FL | $23,275 | 7 |
| , MD | Hematology & Oncology | Washington, DC | $15,506 | 7 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $13,659 | 8 |
| , MD | Internal Medicine | Baltimore, MD | $12,037 | 6 |
| , MD, PHD | Medical Oncology | Boston, MA | $11,259 | 5 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Los Angeles, CA | $11,204 | 4 |
| , M.D | Hematology & Oncology | San Diego, CA | $10,719 | 8 |
| , MD | Internal Medicine | Troy, MI | $10,245 | 7 |
| , MD,PHD | Medical Oncology | Duarte, CA | $9,735 | 5 |
| , M.D | Hematology & Oncology | Philadelphia, PA | $9,700 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $9,700 | 1 |
| , MD | Hematology & Oncology | New Orleans, LA | $9,177 | 8 |
| , MD MPH | Medical Oncology | Boston, MA | $9,150 | 4 |
| , MD | Medical Oncology | New York, NY | $9,150 | 2 |
| Everett Vokes | Hematology & Oncology | Burr Ridge, IL | $8,701 | 5 |
| , M.D | Hematology & Oncology | Sacramento, CA | $7,910 | 4 |
| , MD | Internal Medicine | Tampa, FL | $7,725 | 4 |
| , M.D | Medical Oncology | New York, NY | $7,275 | 1 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Iowa City, IA | $7,265 | 2 |
| , M.D | Specialist | Boston, MA | $6,267 | 4 |
| , M.D | Hematology & Oncology | New York, NY | $6,266 | 7 |
| , M.D | Hematology & Oncology | Germantown, TN | $6,012 | 9 |
| , M.D | Medical Oncology | Houston, TX | $5,825 | 2 |
| , M.D | Hematology & Oncology | Orlando, FL | $5,240 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $11.5M
- NOVARTIS PHARMACEUTICALS CORPORATION $128,989
- Novartis Pharma AG $13,905
Product Information
- Type Drug
- Total Payments $11.6M
- Total Doctors 1,785
- Transactions 3,686
About TABRECTA
TABRECTA is a drug associated with $11.6M in payments to 1,785 healthcare providers, recorded across 3,686 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2024. In 2024, $1.4M was paid across 31 transactions to 9 doctors.
The most common payment nature for TABRECTA is "Unspecified" ($11.3M, 96.9% of total).
TABRECTA is associated with 20 research studies, including "Neratinib and Capmatinib combination in metastatic breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia Signaling Analysis Test" ($1.8M).